Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 2 of 1012345...10...Last »

Student-built exoskeleton mimics human knee

Mechanical engineers from ETH Zurich (Swiss Federal institute of Technology) are developing a new powered exoskeleton that they hope will improve the lives of paraplegics by allowing them to walk with greater freedom than possible with current assisted walking devices. Metal exoskeleton suits worn outside the body, delivering energy for limb movement, are becoming more […]

Read More »

ContextMedia:Health Announces Newest Initiative for Rx Partners: The New Patient Start Program

New service offers partner brands a no-risk approach to drive the marketing outcomes that matter most: new patient starts.

Read More »

Shire Wins Patent Trial Against Watson Concerning LIALDA

The patent for the ulcerative colitis drug LIALDA was upheld and extends through June 8, 2020.

Read More »

Keryx says anemia drug succeeds in study of kidney patients

Keryx Biopharmaceuticals Inc. said its drug to treat iron deficiency anemia in chronic kidney disease patients not yet requiring dialysis met the goals of a late-stage clinical trial.

Read More »

Sanofi Poaches Top AstraZeneca PLC Scientist

March 29, 2016By Mark Terry, Breaking News Staff   Paris-based Sanofi (SNY) announced today that it had appointed Yong-Jun Liu as Head of Research, Global Research and Development starting April 1. He will report to the company’s president of Global Research and Development, Elias Zerhouni. Formerly the head of research at AstraZeneca (AZN)’s MedImmune […]

Read More »

SoCal Biotech TrovaGene’s Stock Tanks After Firing CEO, CFO

March 29, 2016By Mark Terry, Breaking News Staff   San Diego, Calif.-based TrovaGene (TROV) announced yesterday that it had fired the company’s chief executive officer and chief financial officer for cause. The company also filed a lawsuit against both men, Antonius Schuh and Stephen Zaniboni, chief executive officer and chief financial officer, respectively. The […]

Read More »

Biosimilar drugs could save up to $110 billion by 2020: IMS

Lower-cost copies of complex biotech drugs, known as biosimilars, could save the United States and Europe’s five top markets as much as 98 billion euros ($110 bln) by 2020, a new analysis showed on Tuesday. Realizing those savings, however, depends on effective doctor education and healthcare providers adopting smart market access strategies, the report by […]

Read More »

U.S. lawmakers want health agencies to lower prostate cancer drug cost

The patient’s entrance at the National Institutes of Health is shown in Bethesda, Maryland October 16, 2014. Reuters/Gary Cameron <span class="articleLocation”>A group of lawmakers is calling on the National Institutes of Health and Department of Health and Human Services to step in and reduce the cost of Medivation Inc’s and Astellas Pharma Inc’s prostate cancer […]

Read More »

Alder drug to prevent migraines successful in mid-stage study

Alder BioPharmaceuticals Inc. said its injection to prevent migraines had met the main goal in a mid-stage study.

Read More »

A Peek into Pfizer’s R&D Process: from Molecule to Medicine

There’s a slightly hollow feeling about the faded business park which was once home to Pfizer’s bustling R&D community and supported thousands of jobs in the nearby town of Sandwich.

Read More »

China needs tougher enforcement of vaccine regulation: WHO

China must strengthen regulation of its market for vaccines, the World Health Organization (WHO) said on Monday, after a bust of an illegal black market drugs ring this month underscored the country’s regulatory weaknesses. Police have arrested more than 130 suspects over a scandal in which 310 million yuan ($48 million) of illegal vaccines was […]

Read More »

U.S. Alleges Novartis AG Hosted 80,000 ‘Sham’ Events to Wine and Dine Doctors

Novartis AG is under pressure from the U.S. Attorney’s office in Manhattan to provide information about 80,000 “sham” events.

Read More »

Bay Area’s XenoPort Snags Psoriasis and MS Deal Worth $490 Million+

Hyberabad, India-based Dr. Reddy’s Laboratories announced today that it had inked a licensing deal with Santa Clara, Calif.-based XenoPort worth more than $490 million.

Read More »

FDA Scorns Eagle Pharma’s Seven-Year Orphan Drug Exclusivity

March 28, 2016 By Alex Keown, Breaking News Staff   WOODCLIFF LAKE, N.J. – Shares of Eagle Pharmaceuticals EGRX)are down about 8 percent this morning after the U.S. Food and Drug Administration rejected the company’s request for seven years of orphan drug exclusivity in the U.S. for its blood cancer drug, Bendeka. The regulatory […]

Read More »

Pharma Engagement Strategy with IDNs – Embedding in Clinical Pathways

While every medical case is unique, payers and providers are attempting to standardize treatment since unnecessary variation is a major source of growing costs.

Read More »

U.S. spends $3 billion a year on unused cancer drugs

U.S. doctors and hospitals throw out almost $3 billion (roughly 2.7 billion euros) in unused cancer drugs each year because the medicines come in supersized single-use packages and excess medicine must be discarded for safety reasons, a recent paper suggests. Researchers focused on 20 expensive medicines that are given by injection or intravenous drip and […]

Read More »

Transforming The Sales and Marketing Model

The Clinical Specialist Model and the Service Rep Model are considered two of the most successful innovative approaches in S&M for pharmaceutical companies.

Read More »

Terumo Issued Warning Letter Over Destination Guiding Vascular Sheaths

The FDA sent a warning letter to Terumo Corp. over issues with the manufacturing and quality control of its Destination Guiding vascular sheaths.

Read More »

Seven Potential Blockbuster Drugs May Hit The Market This Year

The analysts at Thomson Reuters have consulted their crystal balls and come up with seven drugs coming out this year that will likely hit blockbuster status – defined as marking more than $1 billion annually.

Read More »

Despite Bad-Luck Streak, Gilead Clinches Deal for HQ Expansion

March 25, 2016By Alex Keown, Breaking News Staff   FOSTER CITY, Calif. – Although Gilead Sciences (GILD) is in the midst of a legal battle that could cost it about $3 billion, the Foster City-based company snapped up property in the San Francisco Bay area that could provide 800,000 square-feet of space in an […]

Read More »

Page 2 of 1012345...10...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom